The effects of Cudrania tricuspidata extract on bone metabolism in ovariectomized rats

Jo, You-Young;Seo, Sang Deog;Kim, Ji-Won;Cho, Hyun-Ji;Chon, Jeong-Woo;Lee, Kwang Gill;Lee, Heui-Sam;Park, Yoo-Kyoung;Kweon, HaeYong

  • Received : 2016.06.03
  • Accepted : 2016.06.20
  • Published : 2016.06.30


The effects of Cudrania tricuspidata (CT) extract on markers of osteoporosis were examined in ovariectomized rats. We classified 26 rats into five groups and provided a pellet chow diet and tap water throughout the 27-wk experimental period. During the last 15 wk, we added oral injections to each group as follows: sham-operated (SHAM, n=4) and ovariectomized-control (OVX, n=5) with distilled water, alendronate with 10 mg/kg/d of alendronate sodium (ALEN, n=5), CT (CT100, n=6) with 100 mg/kg/d of CT, and CT (CT300, n=6) with 300 mg/kg/d of CT. After the experimental period, blood, urine, and micro-CT images were assessed. The CT100 and OVX groups did not show any significant differences in urinary n-terminal telopeptide (NTx) (p<0.05 ), but with increases in CT concentration, the NTx level was slightly reduced. Serum osteocalcin was significantly higher in the CT groups than in all other groups (p<0.05 ). Notably, the serum calcium levels of all groups were within the normal range, but urinary calcium levels in the CT groups were significantly lower than the OVX group (p<0.05 ). In addition, the CT groups exhibited higher trabecular BMD than the OVX groups while showing similar BMD to the ALEN group (p<0.05 ). The Tb.Th of the ALEN group was lower than all other groups. Based on the overall analysis of results, CT prevented bone loss by inhibiting bone resorption and enhancing bone formation. Although alendronate showed a similar effect in preventing bone loss, it did so by solely inhibiting bone resorption, and its long-term use reportedly causes paradoxical effects such as hip fractures. Thus, for osteoporosis induced by ovariectomy, we conclude that CT extract is an effective natural treatment without severe side effects.


Cudrania tricuspidata;medicinal herbs;osteocalcin;bone metabolism;ovariectomized rat


  1. Choi MJ Kim MS (2011) Effect of Dietary Vitamin K2 Supplementation on Bone Mineral Density in Ovariectomized Rats. Korean J Nutr 44, 189-195.
  2. Arslan A, Orkun S, Aydin G, Keles I, Tosun A, Arslan M, Caglayan O (2011) Effects of ovariectomy and ascorbic acid supplement on oxidative stress parameters and bone mineral density in rats. Libyan J Med 6, 5965.
  3. Ataoğlu MB, Atik OS, Gül O, Sarıkaya B, Görmeli G, Oztürk BY, Ozgürol B (2013) A comparison of the measurements with biochemical markers of bone turnover and bone mineral density in the assessment of the efficiency of osteoporosis treatment. Eklem Hast Cerrahisi 24, 82-86.
  4. Baeksgaard L, Andersen KP, Hyldstrup L (1998) Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women. Osteoporosis Int 8, 255-260.
  5. Bharadwaj S, Naidu AGT, Betageri GV, Prasadarao NV, Naidu AS (2009) Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women. Osteoporosis Int 20, 1603-1611.
  6. Chen WF, Mok SK, Wang XL, Lai KH, Lai WP, Luk HK, Leung PC, Yao XS, Wong MS (2011) Total flavonoid fraction of the Herba epimedii extract suppresses urinary calcium excretion and improves bone properties in ovariectomised mice. Brit JNutr 105, 180-189.
  7. Choi YJ, Oh HJ, Kim DJ, Lee Y, Chung Y (2012) The prevalence of osteoporosis in Korean adults aged 50 years or older and the higher diagnosis rates in women who were beneficiaries of a national screening program: The Korea National Health and Nutrition Examination Survey 2008–2009. J Bone Miner Res 27, 1879-1886.
  8. Dandinoğlu T, Akarsu S, Karadeniz M, Tekin L, Arıbal S, Kıralp MZ (2013) Can long-term bisphosphonate use causes low-energy fractures? A case report. Osteoporosis Int 25, 773-776.
  9. Epstein S, Delmas PD, Emkey R, Wilson KM, Hiltbrunner V, Schimmer RC (2006) Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Maturitas 54, 1-10.
  10. Imai K (2013) Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging 8, 681-688.
  11. Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye jC, Seronie-Vivien S (2006) Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6, 60.
  12. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ- Brit Med J 341, c4444.
  13. Halasy-Nagy JM, Rodan GA, Reszka AA (2001) Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29, 553-559.
  14. Kalu DN (1991) The ovariectomized rat model of postmenopausal bone loss. Bone and mineral 15, 175-191.
  15. Kanis JA, McCloskey EV (1996) Evaluation of the risk of hip fracture. Bone 18, S127-S132.
  16. Karsenty G, Oury F (2013) Regulation of male fertility by the bone-derived hormone osteocalcin. Mol Cell Endocrinol 382, 521-526.
  17. Kennedy RL, Vangaveti V, Malabu UH, McCulloch D (2013) The vitamin K-dependent Gla proteins and risk of type 2 diabetes. Diabetologia 56, 2100-2101.
  18. Kim MS Kim IA, Ko YJ, Jeong JA, Kim JE, Song BJ, Lim WB, Lim HS, Park JI, Kim SY, Choi HR,Kim OJ (2009) Methanol Extract of Leaves from Cudrania tricuspidata Effects in HT-29 Colorectal Adenocarcinoma. Kor J Oral Maxillofac Pathol 33, 19-26.
  19. Kweon H, Shin SH, Chon JW, Lee K, Jo Y, Yoon JY, Park Y, Jeon J, Kim J, Shin B (2015) Effects of silk fibroin hydrolysate on bone metabolism in ovariecomized rats. Int J Indust Entomol 30, 17-25.
  20. Lim YW, Sun DH, Kim YS (2009) Etiology of Osteoporosis and Prevention of Osteoporotic Fractures (in Korean). J Kor Orthopedic Assoc 21, 6-16.
  21. Lauritzen JB (1996) Hip fractures: incidence, risk factors, energy absorption, and prevention. Bone 18, S65-S75.
  22. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee P J, McKee MD, Jung DY (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456-469.
  23. Li N, Jiang Y, Wooley PH, Xu Z, Yang S (2013) Naringin promotes osteoblast differentiation and effectively reverses ovariectomy-associated osteoporosis. J Orthop Sci 18, 478-485.
  24. Melton LJ, Cummings SR (1987) Heterogeneity of age-related fractures: implications for epidemiology. Bone and mineral 2, 321.
  25. Mizuguchi M, Fujisawa R, Nara M, Nitta K, Kawano K (2001) Fourier-transform infrared spectroscopic study of Ca2+-binding to osteocalcin. Calcified Tissue Int 69, 337-342.
  26. Mundy GR (1991) Inflammatory mediators and the destruction of bone. J Periodontal Res 26, 213-217.
  27. Nordin BEC (1997) Calcium and osteoporosis. Nutrition 13, 664-686.
  28. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocr Metab 90, 1294-1301.
  29. Puchacz E, Lian JB, Stein GS, Wozney J, Huebner K, Croce C (1989) Chromosomal localization of the human osteocalcin gene. Endocrinol 124, 2648-2650.
  30. Rodan GA (1998) Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 38, 375-388
  31. Tranquilli AL, Lucino E, Garzetti GG, Romanini C (1994) Calcium, phosphorus and magnesium intakes correlate with bone mineral content in postmenopausal women. Gynecol Endocrinol 8, 55-58.
  32. Vlasiadis KZ, Damilakis J, Velegrakis GA, Skouteris CA, Fragouli I, Goumenou A, Matalliotakis J, Koumantakis EE (2008) Relationship between BMD, dental panoramic radiographic findings and biochemical markers of bone turnover in diagnosis of osteoporosis. Maturitas 59, 226-233.


Grant : 누에의 바이오 프린팅 기구를 활용한 3D 실크 매트릭스 제조 기술 개발

Supported by : 국립농업과학원